Regeneron Pharmaceuticals Inc (REGN)
959.72
-4.75
(-0.49%)
USD |
NASDAQ |
Mar 18, 16:00
959.92
+0.20
(+0.02%)
Pre-Market: 09:03
Price Chart
Key Stats
Price and Performance | |
---|---|
Market Cap | 105.34B |
52 Week High (Daily) | Upgrade |
52 Week Low (Daily) | Upgrade |
All-Time High (Daily) | Upgrade |
Year to Date Total Returns (Daily) | Upgrade |
1 Month Total Returns (Daily) | Upgrade |
1 Year Total Returns (Daily) | 28.36% |
Valuation | |
PE Ratio | 27.62 |
PE Ratio (Forward) | Upgrade |
PS Ratio | 8.322 |
Price to Book Value | 4.056 |
EV to EBITDA | Upgrade |
Dividend | |
---|---|
Dividend | -- |
Dividend Yield (Forward) | Upgrade |
Financials | |
Revenue (5 Year Growth) | Upgrade |
Revenue (Quarterly YoY Growth) | Upgrade |
EPS Diluted (5 Year Growth) | Upgrade |
EPS Diluted (Quarterly YoY Growth) | Upgrade |
Debt to Equity Ratio | 0.0763 |
Return on Equity | Upgrade |
Return on Assets | Upgrade |
Risk | |
Beta (5Y) | Upgrade |
Max Drawdown (5Y) | 53.84% |
Profile
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases; Praluent for LDL cholesterol lowering; Dupixent in immunology; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and CRISPR-based gene editing (Intellia). |
URL | https://www.regeneron.com |
Investor Relations URL | https://investor.regeneron.com/ |
HQ State/Province | New York |
Sector | Healthcare |
Industry | Biotechnology |
Equity Style | Large Cap/Blend |
Next Earnings Release | May. 03, 2024 (est.) |
Last Earnings Release | Feb. 02, 2024 |
Next Ex-Dividend Date | N/A |
Last Ex-Dividend Date | N/A |
Ratings
Profile
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases; Praluent for LDL cholesterol lowering; Dupixent in immunology; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and CRISPR-based gene editing (Intellia). |
URL | https://www.regeneron.com |
Investor Relations URL | https://investor.regeneron.com/ |
HQ State/Province | New York |
Sector | Healthcare |
Industry | Biotechnology |
Equity Style | Large Cap/Blend |
Next Earnings Release | May. 03, 2024 (est.) |
Last Earnings Release | Feb. 02, 2024 |
Next Ex-Dividend Date | N/A |
Last Ex-Dividend Date | N/A |